This site is intended for healthcare professionals
News

Tagrisso approved in the EU for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer.- AstraZeneca

Read time: 1 mins
Last updated:28th May 2021
Published:29th May 2021
AstraZeneca’s Tagrisso (osimertinib) has been approved in the European Union (EU) for the adjuvant treatment of adult patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent.
Condition: NSCLC / EGFR
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest